WillItSurvive
Pharma and healthcare groups · China

Zai Lab

zailaboratory.com ↗

China-based biopharma commercializing ZEJULA and VYVGART, betting growth on pipeline drug zocilurtatug.

Losing its protection
Assessed 24 July 2026 · Evidence as of 24 July 2026
The structural protection is eroding.
On the recordSince 24 July 2026 · Checkable from August 6, 2026 · Every call on the record Checkpoint: Q2 2026 earnings release, first full quarter under new leadership after COO departure
The call

Zai Lab's growth case now rests on zocilurtatug's 2026-2027 trial data, while generics and price cuts wear down its two approved drugs in the meantime.

Zai Lab makes and sells cancer medicines approved in China and the US, generating real sales of $460 million. However, its two main moneymakers, ZEJULA and VYVGART, are losing market share to cheaper generic copies and being forced into lower prices by the Chinese government. The company is not facing replacement by AI or Western rivals in its home market, but Chinese generic drugmakers are directly undercutting its prices. Almost all future hope rests on a single experimental drug called zocilurtatug, which is still in late-stage testing and needs approval from regulators sometime in the next one to two years. If that drug fails or delays significantly while the older products keep losing sales, the company's growth story collapses.

Why
01
AI pressure: None apparent. AI cannot replicate NRDL listings or drug approvals; Zai Lab's own AI-in-R&D claims are unverified marketing, not a threat vector. Could AI do the core job? Unlikely.
02
Bigger players: Chinese generic drugmakers and NRDL price cuts. Generic entrants and government-mandated price cuts are already eroding ZEJULA and VYVGART revenue, not just threatening to. Could a giant copy it? Probably.
03
What protects it. NRDL listings, China regulatory approvals, and licensing ties to Amgen and Boehringer give access Western rivals can't easily copy.
What would change this call
Zai Lab Q2/Q3 2026 revenue trend versus Q1 2026's 6% YoY decline. Shows whether ZEJULA/VYVGART erosion is stabilizing or accelerating.
Zoci Phase 3 combination data readout, expected H2 2026. Tests whether the next growth driver is clinically viable.
Zoci global BLA filing timeline, expected late 2027. Shows whether the pipeline bet is on track or slipping.
Key numbers
  • FY2025 revenue $460.2M, up 15% YoY (2026-02-26)
  • Q4 2025 revenue $127.6M, up 17% YoY (2026-02-26)
  • President/COO Josh Smiley departed (2026-05-22)
Named risks
  • Entire growth thesis depends on zoci Phase 3 success and 2027 BLA filing, still unproven. Severity: high
  • ZEJULA revenue continuing to erode from Chinese generic competition. Severity: high
  • Recurring NRDL-mandated price cuts squeezing VYVGART and other reimbursed drugs. Severity: medium
  • President/COO departure in May 2026 during critical pipeline execution period. Severity: medium
  • Operating losses widening (23% YoY in Q1 2026) while revenue guidance already missed once in 2025. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
BeiGenecontestingNamed as regional peer competing for global licensing deals, per FierceBiotech April 2026
Chinese generic drugmakerslosing toGeneric competition cited as cause of ZEJULA revenue erosion through Q1 2026
Amgen (IMDELLTRA/tarlatamab)contestingAmgen's approved DLL3 drug tarlatamab competes in same class as zoci; also a 2026 trial partner
Innovent BiologicscontestingCited as Chinese biopharma peer with overlapping oncology licensing ambitions
Questions people ask
Is Zai Lab profitable in 2026?
No. Zai Lab posted a Q1 2026 net loss of $51.0 million and an operating loss of $69.4 million, up 23% year over year, as reported May 7, 2026. Full-year 2025 revenue was $460.2 million but the company remains unprofitable while it funds pipeline development toward a projected 2027 return to growth.
Who owns Zai Lab?
Zai Lab is an independent, publicly traded company with no parent entity, listed on Nasdaq as ZLAB since September 2017 and on the Hong Kong Stock Exchange as 9688 since September 2020. Its market capitalization was approximately $2.3 billion as of July 23, 2026, per gurufocus.com.
Who is Zai Lab's biggest competitor?
Zai Lab is not primarily threatened by Western multinationals but by domestic Chinese rivals: BeiGene competes for similar global licensing deals (FierceBiotech, April 2026), while Chinese generic drugmakers are already eroding ZEJULA's market share and NRDL price cuts hit VYVGART by 12% in the 2025 renewal.
Could AI replace Zai Lab?
No. Zai Lab's core value comes from regulatory approvals, NRDL drug listings, and licensing agreements that AI cannot replicate. The company says it is 'embedding AI across R&D and commercial' functions (vendor-claimed, per its Q1 2026 report), but this is framed as a productivity tool, not a substitute for its approved drug portfolio.
Why did Zai Lab's revenue fall in 2026?
Q1 2026 revenue dropped 6% year over year to $99.6 million, reported May 7, 2026, driven by generic competition eroding ZEJULA sales and a 12% NRDL-mandated price cut on VYVGART. Management guided toward sequential improvement through 2026 and a return to growth in 2027.
What is zocilurtatug and why does it matter for Zai Lab?
Zocilurtatug (zoci), a DLL3-targeting antibody-drug conjugate licensed from MediLink Therapeutics, is in a global Phase 3 trial (DLLEVATE) for small cell lung cancer, with FDA Fast Track designation from May 2025. Enrollment is expected to complete H1 2027, with a first global BLA filing targeted late 2027; it is central to Zai Lab's growth thesis.
Timeline
  • 2026-07-22Company announces Q2 2026 earnings date of August 6, 2026 and confirms Smiley departure
  • 2026-05-22President and COO Josh Smiley departs Zai Lab
  • 2026-05-07Q1 2026 revenue falls 6% YoY to $99.6 million; net loss $51.0 million
  • 2026-04-01Amgen and Boehringer Ingelheim clinical collaborations announced for zoci combinations
  • 2026-03-01Vertex povetacicept Phase 3 RAINIER trial hits endpoint in IgA nephropathy
  • 2026-02-26FY2025 revenue reported at $460.2 million, up 15% YoY, below original guidance
  • 2025-12-01First patient dosed in global Phase 1/1b trial of ZL-1503 for atopic dermatitis
  • 2025-05-01Zocilurtatug (zoci) receives FDA Fast Track designation
  • 2020-09-01Secondary listing completed on Hong Kong Stock Exchange (9688)
  • 2017-09-01Zai Lab completes Nasdaq IPO (ZLAB)
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Community Health SystemsViatrisAccendra Health
More in Pharma and healthcare groups →
Sources